research chemicals tirzepatide (GLP-1/GIP) - 5mg Tirzepatide 10mg – Dual GIP/GLP-1

The key advantage is portability to appointments without device dependence

Over half of states that contract with MCOs report targeted carve-outs of one or more drugs or drug classes

Key therapeutic benefits include: Significant reductions in HbA1c (up to 2.02.5% in clinical trials) Substantial weight loss (up to 15% body weight reduction in type 2 diabetes and up to 22% in people without diabetes at the 15 mg dose) Cardiovascular risk factor improvements Once-weekly dosing for improved adherence Tirzepatide is not indicated for type 1 diabetes and should be used with caution or avoided in pregnancy and breastfeeding

It found that those who had to pay $50 or more each month were 50% less likely to keep taking the medications compared to those who paid less than $10